A new pill that combats antibiotic-resistant strains of gonorrhoea has inched closer to approval in the US, after the US Food and Drug Administration (FDA) accepted GSK’s gepotidacin for priority ...

Assembly Biosciences is advancing its herpes drug to Phase II trials after it showed 94% antiviral efficacy in a Phase Ib ...

GSK (GSK) stock in focus as the company bid to expand use of oral antibiotic agent gepotidacin for urogenital gonorrhea is granted FDA priority review. Read more here.